11β-hydroxysteroid dehydrogenase type 1 gene expression is increased in ascending aorta tissue of metabolic syndrome patients with coronary artery disease.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Genetics and Molecular Research

• Publication date

  2012-08-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4238/2012.AUGUST.31.10PMID 23007990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity.

  2011cited by this paper
• 11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation.

  2010cited by this paper
• Expression of adrenomedullin in human epicardial adipose tissue: role of coronary status.

  2007cited by this paper
• Type 2 diabetes and metabolic syndrome are associated with increased expression of 11β-hydroxysteroid dehydrogenase 1 in obese subjects

  2007cited by this paper
• Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.

  2007cited by this paper
• Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes.

  2007cited by this paper
• 11β‐HSD Type 1 Expression in Human Adipose Tissue: Impact of Gender, Obesity, and Fat Localization

  2007influential reference
• Role of 11-beta-hydroxysteroid dehydrogenase type 1 in differentiation of 3T3-L1 cells and in rats with diet-induced obesity

  2006cited by this paper
• 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.

  2006cited by this paper
• Characterisation of 11β-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat

  2006cited by this paper
• Cardiovascular Diabetology BioMed Central Original investigation Increased proinflammatory endothelial response to S100A8/A9

  2006cited by this paper
• 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.

  2005cited by this paper
• Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart

  2005cited by this paper
• Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease.

  2005cited by this paper
• Postnatal diet-induced obesity in rats upregulates systemic and adipose tissue glucocorticoid metabolism during development and in adulthood: its relationship with the metabolic syndrome.

  2005cited by this paper
• Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease.

  2004cited by this paper
• 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.

  2004influential reference
• Chemokines: Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease

  2004cited by this paper
• Lipids, lipoproteins and apolipoproteins among turks, and impact on coronary heart disease.

  2004cited by this paper
• Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk.

  2003cited by this paper
• Chronic stress and obesity: A new view of “comfort food”

  2003cited by this paper
• Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.

  2003cited by this paper
• Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.

  2003cited by this paper
• Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.

  2003cited by this paper
• The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study.

  2003cited by this paper
• Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians.

  2003cited by this paper
• A switch in dehydrogenase to reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells.

  2002cited by this paper
• 11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol.

  2002cited by this paper
• 11Beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart.

  2002cited by this paper
• 11β-Hydroxysteroid Dehydrogenase 1 Transforms 11-Dehydrocorticosterone into Transcriptionally Active Glucocorticoid in Neonatal Rat Heart.

  2002cited by this paper
• A Transgenic Model of Visceral Obesity and the Metabolic Syndrome

  2001cited by this paper
• PPARα Agonists Reduce 11β-Hydroxysteroid Dehydrogenase Type 1 in the Liver

  2000cited by this paper
• PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver.

  2000cited by this paper
• Clustering of metabolic factors and coronary heart disease.

  1999cited by this paper
• Differentiation of Adipose Stromal Cells: The Roles of Glucocorticoids and 11β-Hydroxysteroid Dehydrogenase.

  1999cited by this paper
• Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase.

  1999cited by this paper
• Chemokines and atherosclerosis.

  1999cited by this paper
• Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group.

  1998cited by this paper
• Does central obesity reflect "Cushing's disease of the omentum"?

  1997cited by this paper
• 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress.

  1997cited by this paper
• 11 b-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress

  1997cited by this paper
• Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link

  1994influential reference
• Steroid hormone receptors in human adipose tissues.

  1990cited by this paper

• Nouveaux dérivés d'aza-tétracyclo

  2017cites this paper
• Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.

  2017cites this paper
• Cellular distribution and interaction between extended renin-angiotensin-aldosterone system pathways in atheroma.

  2017cites this paper
• Cortisol Metabolism as a Regulator of the Tissue-Specific Glucocorticoid Action

  2017cites this paper
• Dérivés aza-tétra-cycliques

  2016cites this paper
• The Dehydrogenase Hypothesis.

  2015cites this paper
• Transcriptome and Molecular Endocrinology Aspects of Epicardial Adipose Tissue in Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Observational Studies

  2015cites this paper
• The cardioprotective effects of mineralocorticoid receptor antagonists.

  2014cites this paper
• 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects.

  2013cites this paper
• Pro-Inflammatory Cytokine Induction of 11β-hydroxysteroid Dehydrogenase Type 1 in A549 Cells Requires Phosphorylation of C/EBPβ at Thr235

  2013cites this paper
• Pro-Inflammatory Cytokine Induction of 11 β-hydroxysteroid Dehydrogenase Type 1 in A 549 Cells Requires Phosphorylation of C / EBPβ at Thr 235

  2013cites this paper
• 11β-HSD1 Inhibitors for the Treatment of Type 2 Diabetes and Cardiovascular Disease

  2013cites this paper
• Modulation of 11β-Hydroxysteroid Dehydrogenase as a Strategy to Reduce Vascular Inflammation

  2013cites this paper